PathGroup Launches Cancer-Specific Testing Product

PathGroup is launching its cancer-specific SmartGenomics testing platform, which features diagnostic panels targeting lung, colon, brain, thyroid and melanoma/GIST cancers in newly diagnosed patients.

The product offers an individualized genomic baseline of a patient’s cancer, linking the panels to specific treatment options, the company says.

In addition, the product is comprised of 85 gene panels for relapsed or refractory tumors and boasts a genome array analysis that includes more than 22,000 genes.

Brentwood, Tenn.-based PathGroup was founded in 1965. — Jason Scott